

# Mohid S Khan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3004286/publications.pdf>

Version: 2024-02-01

16  
papers

253  
citations

1163117

8  
h-index

1199594

12  
g-index

16  
all docs

16  
docs citations

16  
times ranked

339  
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms. <i>Clinical Cancer Research</i> , 2016, 22, 79-85.	7.0	65
2	Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013â€“2015. <i>British Journal of Cancer</i> , 2019, 121, 966-972.	6.4	44
3	Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres. <i>World Journal of Gastroenterology</i> , 2019, 25, 5991-6005.	3.3	43
4	Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours. <i>British Journal of Cancer</i> , 2019, 120, 294-300.	6.4	25
5	Is local excision sufficient in selected grade 1 or 2 type III gastric neuroendocrine neoplasms?. <i>Endocrine</i> , 2021, 74, 421-429.	2.3	15
6	A guide to midgut neuroendocrine tumours (NETs) and carcinoid syndrome. <i>Frontline Gastroenterology</i> , 2015, 6, 264-269.	1.8	14
7	Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review. <i>Advances in Therapy</i> , 2021, 38, 969-993.	2.9	11
8	Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review. <i>World Journal of Gastroenterology</i> , 2020, 26, 4537-4556.	3.3	10
9	Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13096.	2.6	9
10	Neuroendocrine tumours: what gastroenterologists need to know. <i>Frontline Gastroenterology</i> , 2022, 13, 50-56.	1.8	8
11	Patient Survey of the Physical, Emotional, and Informational Challenges for Patients Living with Neuroendocrine Tumors. <i>Oncology and Therapy</i> , 2020, 8, 67-80.	2.6	2
12	Evaluation of faecal elastase 1 in symptomatic patients with neuroendocrine tumours. <i>Endocrine Abstracts</i> , 0, , .	0.0	2
13	Nutritional assessment and vitamin deficiencies in patients with NETs. <i>Endocrine Abstracts</i> , 0, , .	0.0	2
14	Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours. <i>European Journal of Cancer</i> , Supplement, 2021, 16, 5-13.	2.2	2
15	Improving diagnosis times as part of the transformation of the South Wales NET Service. <i>Endocrine Abstracts</i> , 0, , .	0.0	1
16	Physical, emotional, and informational challenges of patients living with neuroendocrine tumors in the United States: Understanding their unmet needs.. <i>Journal of Clinical Oncology</i> , 2018, 36, 299-299.	1.6	0